DUSC public release documents by meeting

October 2025

• Analysis of the utilisation of treatments for chronic lymphocytic leukaemia or small lymphocytic lymphoma, October 2025
• Analysis of daratumumab for newly diagnosed systemic light chain amyloidosis, October 2025
• Analysis of elexacaftor + tezacaftor + ivacaftor (&) ivacaftor for cystic fibrosis utilisation, October 2025

June 2025

• Analysis of atezolizumab for hepatocellular carcinoma, June 2025
• Analysis of cemiplimab for cutaneous squamous cell carcinoma, June 2025
• Analysis of nivolumab for gastro-oesophageal cancers, June 2025
• Analysis of nusinersen for spinal muscular atrophy (adults), June 2025

April 2025

• Analysis of fluticasone furoate+umeclidinium+vilanterol and single inhaler triple therapies for severe asthma, April 2025
• Analysis of Gastrointestinal stromal tumour (GIST) listings, April 2025
• Analysis of zanubrutinib for Waldenström macroglobulinaemia, April 2025

October 2024

• Analysis of dasatinib and nilotinib for chronic myeloid leukaemia, October 2024
• Analysis of idelalisib for refractory follicular B-cell non-Hodgkin lymphoma, October 2024
• Analysis of molnupiravir for SARS-CoV-2 infection, October 2024

June 2024

• Analysis of brentuximab vedotin for cutaneous and peripheral T-cell lymphoma, June 2024
• Analysis of galcanezumab and fremanezumab for chronic migraine, June 2024
• Analysis of semaglutide for Type 2 diabetes mellitus, June 2024

February 2024

• Analysis of nivolumab and ipilimumab for mesothelioma, February 2024
• Analysis of dupilumab for asthma, February 2024
• Analysis of romosozumab for osteoporosis, February 2024
• Analysis of progesterone for preterm birth, February 2024

September 2023

• Analysis of dupilumab for severe atopic dermatitis, September 2023
• Analysis of Pharmaceutical Benefits Scheme (PBS) and Repatriation PBS (R/PBS) listed medicines used in the management of attention deficit hyperactivity disorder, September 2023
• Analysis of apremilast for severe chronic plaque psoriasis, September 2023
• Analysis of venetoclax for first-line treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma, September 2023

June 2023

• Analysis of olaparib for ovarian, fallopian tube and primary peritoneal cancer, June 2023
• Analysis of impact of regulatory reforms on utilisation of opioids, June 2023
• Analysis of omalizumab for chronic spontaneous urticaria, June 2023

February 2023

• Analysis of evolocumab for hypercholesterolaemia, February 2023

September 2022

• Analysis of medicines for the treatment of non-small cell lung cancer, including a predicted versus actual analysis of durvalumab, September 2022
• Medicines for the treatment of type 2 diabetes, September 2022
• Nivolumab as adjuvant treatment of melanoma: 24 month predicted versus actual analysis and melanoma market review, September 2022
• Atezolizumab for extensive-stage small cell lung cancer: analysis of predicted versus actual utilisation, September 2022

June 2022

• Analysis of proton pump inhibitor (PPI) medicines used in the management of gastrointestinal acid related disorders, June 2022
• Teduglutide for Short Bowel Syndrome: 24 month predicted versus actual analysis, June 2022

February 2022

• Analysis of medicines for the treatment of locally advanced and metastatic breast cancer: including a 24 month predicted versus actual analysis of palbociclib, February 2022
• Avelumab for Merkel cell carcinoma: 24 month predicted versus actual analysis, February 2022
• Cladribine for relapsing remitting multiple sclerosis: predicted versus actual analysis, February 2022

October 2021

• Golimumab for non-radiographic axial spondyloarthritis, October 2021
• Nivolumab plus Ipilimumab for first-line Stage IV clear cell variant renal cell carcinoma, October 2021
• Pembrolizumab for locally advanced or metastatic urothelial carcinoma, October 2021
• Bictegravir+emtricitabine+tenofovir alafenamide and dolutegravir+rilpivirine for HIV, October 2021
• NPS analysis on HIV and PrEP medications using MedicineInsight and PBS data, October 2021
• Tolvaptan for autosomal dominant polycystic kidney disease

June 2021

• Evolocumab for heterozygous familial hypercholesterolaemia, June 2021
• Guanfacine for attention deficit hyperactivity disorder, June 2021
• Somatropin for growth hormone therapy, June 2021

February 2021

• Ocular lubricants utilisation analysis PBS data, February 2021
• Ocular lubricants utilisation analysis MedicineInsight data, February 2021
• Nusinersen for spinal muscular atrophy, February 2021

October 2020

• Adrenaline autoinjectors utilisation analysis, October 2020
• Alectinib for non-small cell lung cancer, October 2020
• Denosumab for osteoporosis, October 2020
• Eculizumab for atypical haemolytic uremic syndrome (aHUS), October 2020
• Ibrutinib for chronic lymphocytic leaukaemia/ small lymphocytic lymphoma, October 2020
• Ocrelizumab for relapsing-remitting multiple sclerosis, October 2020

June 2020

• Nivolumab for non-small cell lung cancer, June 2020
• Nivolumab for renal cell carcinoma, June 2020
• Omalizumab for chronic spontaneous urticaria, June 2020

February 2020

• Alemtuzumab for relapsing remitting multiple sclerosis: 24 month predicted versus actual analysis, February 2020
• Idiopathic pulmonary fibrosis: 24 month predicted versus actual analysis, February 2020
• Opioid Analgesics, February 2020
• Testosterone, February 2020

October 2019

• Lenalidomide for newly diagnosed multiple myeloma, October 2019
• Tyrosine kinase inhibitors for chronic myeloid leukaemia, October 2019
• Biologics for uncontrolled severe allergic and eosinophilic asthma, October 2019
• Evolocumab for homozygous familial hypercholesterolaemia, October 2019

June 2019

• Armodafinil, 24 month predicted versus actual analysis, June 2019
• GnRH Agonists, Utilisation analysis, June 2019
• Sapropterin, 24 month predicted versus actual analysis, June 2019

February 2019

• Bendamustine for the treatment of lymphoma: 24 month predicted versus actual analysis, February 2019
• Eculizumab for aHUS: utilisation update, February 2019

September 2018

• Bevacizumab for epithelial ovarian, fallopian tube or primary peritoneal cancer 24 months review, September 2018
• Direct acting antiviral medicines for the treatment of chronic hepatitis C, September 2018
• Febuxostat for gout 24 months review, September 2018
• Ruxolitinib for myelofibrosis 24 months review, September 2018

May 2018

• Attention Deficit Hyperactivity Disorder, May 2018
• Botulinum toxin for spasticity and dystonia, May 2018
• Ranibizumab and aflibercept: analysis of use for AMD, DMO and RVO, May 2018
• Medicines for the treatment of melanoma, May 2018
• Posaconazole 24 month review, May 2018

February 2018

• Metastatic colorectal cancer, February 2018
• Medicines for HER2 positive metastatic breast cancer, February 2018
• Ivacaftor for cystic fibrosis, February 2018

September 2017

• 5-aminosalicylic acids for ulcerative colitis
• Eculizumab for aHUS
• Everolimus and sunitinib for pNET
• Lenalidomide for myelodysplastic syndrome
• Nab-paclitaxel for pancreatic cancer
• Multiple myeloma

June 2017

• Botulinum toxin for chronic migraine, June 2017
• Crohn disease, June 2017
• Ulcerative colitis, June 2017

February 2017

• Erlotinib and gefitinib for non-small cell lung cancer 24 month review, February 2017
• Everolimus for breast cancer 24 month review, February 2017
• Everolimus for tuberous sclerosis complex 24 month review, February 2017
• Ferric carboxymaltose 24 month review, February 2017
• Imatinib for gastrointestinal stromal tumour 24 month review, February 2017
• Medicines for diabetes, February 2017

September 2016

• Antifungals for systemic use, September 2016
• Antipsychotic medicines and 25 mg quetiapine 24 month review, September 2016
• Mifepristone and misoprostol, September 2016
• Medicines for osteoporosis, September 2016
• Rifaximin 24 month review, September 2016
• Testosterone, September 2016

June 2016

• bDMARDs for ankylosing spondylitis, June 2016
• Medicines for glaucoma, June 2016
• Novel oral anticoagulants for non-valvular atrial fibrillation, June 2016
• Oral medicines for metastatic prostate cancer, June 2016

February 2016

• Medicines for Alzheimer disease, February 2016
• bDMARDs for ankylosing spondylitis, February 2016
• bDMARDs for psoriatic arthritis, February 2016
• Smoking cessation therapy, February 2016
• Ticagrelor, February 2016

October 2015

• Alprazolam, October 2015
• bDMARDS for psoriatic arthritis, October 2015
• Ipilimumab and dabrafenib for unresectable melanoma, October 2015
• Multiple Sclerosis, October 2015
• Nutritional products, October 2015
• Pregabalin 24 month review, October 2015

June 2015

• Aflibercept and ranibizumab for age-related macular degeneration, June 2015 ¹
• Attention deficit hyperactivity disorder, June 2015
• Dutasteride and dutasteride with tamsulosin for benign prostatic hyperplasia, June 2015
• Icatibant for hereditary angioedema, June 2015
• Romiplostim and eltrombopag for idiopathic thrombocytopenic purpura, June 2015

February 2015

• Antibiotics, October 2014 and February 2015
• bDMARDs for Crohn's disease, February 2015
• Hepatitis B, February 2015
• Pulmonary Arterial hypertension, February 2015

October 2014

• Antibiotics, October 2014 and February 2015
• Cystic fibrosis: tobramycin inhalation 24 month review, October 2014
• Cystic fibrosis: dornase and mannitol, October 2014
• Exenatide, October 2014
• Ezetimibe with simvastatin, October 2014
• Novel oral anticoagulants for deep vein thrombosis, pulmonary embolism and recurrent venous thromboembolism, October 2014
• Opioids, October 2014
• Pregabalin 12 month review, October 2014

June 2014

• Bone metastases, June 2014
• bDMARDs for chronic plaque psoriasis, June 2014
• Ocular lubricants, June 2014
• Omalizumab 24 month review, June 2014
• Pazopanib and sunitinib for renal cell carcinoma, June 2014

February 2014

• Iron chelating agents, February 2014
• Tyrosine kinase inhibitors for the treatment of chronic myeloid leukaemia, February 2014

June 2013

• Antipsychotics in children and adolescents, February 2013 & June 2013
• Antipsychotics in the middle aged, February 2013 & June 2013

February 2013

• Antipsychotics in children and adolescents, February 2013 & June 2013
• Antipsychotics in the middle aged, February 2013 & June 2013
• Type 2 diabetes, October 2012 and February 2013

October 2013

• Testosterone, October 2012
• Type 2 diabetes, October 2012 and February 2013

Suggested citation: [1] Department of Health. Age Related Macular Degeneration: utilisation analysis. Canberra: Department of Health; 2015. Available from http://www.pbs.gov.au/info/industry/listing/participants/public-release-docs/aflibercept-ranibizumab-prd-2015-06